83268-76-2

Upstream product

• 83268-72-8 (E-trans)-4-(tert-butyldimethylsiloxy)-6-<2-(2,4-dichlorophenyl)ethenyl>-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 83268-73-9 (E)-4β-(tert-butyldimethylsiloxy)-6α-<2-(2,4-dichlorophenyl)ethenyl>-3,4,5,6-tetrahydro-2H-pyran-2-ol 
• 83268-74-0 (E)-(3R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-1-(2,4-dichloro-phenyl)-7-[1,3]dithian-2-ylidene-hept-1-en-3-ol 
• 86097-37-2 trans-(E)-6-[2-(2,4-dichlorophenyl)ethenyl]-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 83268-75-1 (E-trans)-5-(tert-butyldimethylsiloxy)-7-<2-(2,4-dichlorophenyl)ethenyl>-2,2-(trimethylenedithio)hexahydrooxepin 

Relevant academic research and scientific papers

Structural Modification of Mevinolin

Synthetic strategies are described for modifying the side-chain ester and lactone moieties of mevinolin (1), a potent, competitive HMG-CoA reductase inhibitor isolated from cultures of Aspergillus terreus.A general route for preparing side-chain ether analogues of 1 is disclosed.Central to the success of this multistep route is the use of a method for reversibly masking the lactone moiety as a hemiacetal ether.The merit of this strategy is demonstrated again in the route developed for elaborating mevalonate analogue 11 from 1.Finally, a new, versatile, and efficientmethod is presented for homologating five- and six-membered lactones and is used to prepare carboxylate 27, a homologue of 1.